Brian A. Markison net worth and biography

Brian Markison Biography and Net Worth

Director of Lantheus

Brian Markison is the Non-Executive Chairman of the Board of Directors and is also a member of the Science and Technology Committee. Mr. Markison joined the Board of Directors in September 2012 and was elevated to Chairman in January 2013. Mr. Markison has been a Healthcare Industry Executive for Avista since September 2012. Mr. Markison is a seasoned executive with more than 30 years of operational, marketing, commercial development and sales experience with international pharmaceutical companies. He is currently the Chief Executive Officer and a Director of Osmotica Holdings, SCSp, after serving as Executive Chairman of one of its predecessor companies, Vertical/Trigen Holdings, LLC. Previously, he held the position of President and Chief Executive Officer and member of the Board of Directors of Fougera Pharmaceuticals Inc., a specialty pharmaceutical company in dermatology, prior to its sale to Sandoz, the generics division of Novartis AG. Before leading Fougera, Mr. Markison was Chairman and Chief Executive Officer of King Pharmaceuticals, which he joined as Chief Operating Officer in March 2004, and was promoted to President and Chief Executive Officer later that year and elected Chairman in 2007. Prior to joining King, Mr. Markison held various senior leadership positions at Bristol-Myers Squibb, including President of Oncology, Virology and Oncology Therapeutics Network; President of Neuroscience, Infectious Disease and Dermatology; and Senior Vice President, Operational Excellence and Productivity. Mr. Markison also serves on the Board of Directors of Cosette Pharmaceuticals. He is also a Director of the College of New Jersey. Mr. Markison holds a Bachelor of Science degree from Iona College.

What is Brian A. Markison's net worth?: The estimated net worth of Brian A. Markison is at least $1.67 million as of March 27th, 2023. Mr. Markison owns 19,318 shares of Lantheus stock worth more than $1,670,041 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Markison may own. Additionally, Mr. Markison receives an annual salary of $139,190.00 as Director at Lantheus. Learn More about Brian A. Markison's net worth.
How old is Brian A. Markison?: Mr. Markison is currently 65 years old. There are 5 older executives and no younger executives at Lantheus. Learn More on Brian A. Markison's age.
What is Brian A. Markison's salary?: As the Director of Lantheus Holdings, Inc., Mr. Markison earns $139,190.00 per year. There are 3 executives that earn more than Mr. Markison. The highest earning executive at Lantheus is Mr. Robert J. Marshall Jr., CFA, CFO & Treasurer, who commands a salary of $1,300,000.00 per year. Learn More on Brian A. Markison's salary.
How do I contact Brian A. Markison?: The corporate mailing address for Mr. Markison and other Lantheus executives is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. Lantheus can also be reached via phone at (978) 671-8001 and via email at [email protected]. Learn More on Brian A. Markison's contact information.
Has Brian A. Markison been buying or selling shares of Lantheus?: Brian A. Markison has not been actively trading shares of Lantheus during the past quarter. Most recently, Brian A. Markison sold 13,290 shares of the business's stock in a transaction on Monday, March 27th. The shares were sold at an average price of $81.13, for a transaction totalling $1,078,217.70. Following the completion of the sale, the director now directly owns 19,318 shares of the company's stock, valued at $1,567,269.34. Learn More on Brian A. Markison's trading history.
Who are Lantheus' active insiders?: Lantheus' insider roster includes Minnie Baylor-Henry (Director), Gerard Ber (Director), Paul Blanchfield (Insider), John Bolla (COO), Michael Duffy (SVP), Mary Heino (CEO), Sam Leno (Director), Heinz Maeusli (Director), Brian Markison (Director), Robert Marshall, Jr. (CFO), Etienne Montagut (Insider), Daniel Niedzwiecki (Insider), Gary Pruden (Director), Andrea Sabens (CAO), and Carol Walker (SVP). Learn More on Lantheus' active insiders.
Are insiders buying or selling shares of Lantheus?: During the last year, Lantheus insiders bought shares 1 times. They purchased a total of 60,431,039 shares worth more than $57,409,487.05. During the last year, insiders at the medical equipment provider sold shares 13 times. They sold a total of 167,666 shares worth more than $12,647,453.05. The most recent insider tranaction occured on August, 12th when Director Gerard Ber sold 15,500 shares worth more than $1,495,440.00. Insiders at Lantheus own 2.1% of the company. Learn More about insider trades at Lantheus.
Information on this page was last updated on 8/12/2024.

Brian A. Markison Insider Trading History at Lantheus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/27/2023	Sell	13,290	$81.13	$1,078,217.70	19,318
9/8/2022	Sell	41,812	$84.24	$3,522,242.88	32,608
7/10/2019	Sell	4,918	$28.07	$138,048.26	27,549
7/3/2019	Sell	5,000	$28.41	$142,050.00	32,467
6/26/2019	Sell	5,000	$27.67	$138,350.00	37,467
6/19/2019	Sell	5,000	$27.40	$137,000.00	42,467
6/12/2019	Sell	5,000	$25.27	$126,350.00	47,467
5/29/2019	Sell	5,000	$24.29	$121,450.00	57,467
5/22/2019	Sell	5,000	$24.73	$123,650.00	62,467
5/15/2019	Sell	5,000	$24.75	$123,750.00	67,467
5/8/2019	Sell	5,000	$25.22	$126,100.00	72,467
5/1/2019	Sell	10,000	$24.11	$241,100.00
4/23/2019	Sell	5,000	$24.07	$120,350.00	87,467
4/16/2019	Sell	5,000	$25.26	$126,300.00	92,467

Brian A. Markison Buying and Selling Activity at Lantheus

Lantheus Company Overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Today's Range

Now: $86.45

$82.14

$86.60

50 Day Range

MA: $103.76

$76.22

$116.69

2 Week Range

Now: $86.45

$50.20

$126.89

Volume

2,026,315 shs

Average Volume

1,014,213 shs

Market Capitalization

$6.01 billion

P/E Ratio

14.38

Dividend Yield

N/A

Beta

0.51

Watch this before it gets removed

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

Brian Markison Biography and Net Worth

What is Brian A. Markison's net worth?

How old is Brian A. Markison?

What is Brian A. Markison's salary?

How do I contact Brian A. Markison?

Has Brian A. Markison been buying or selling shares of Lantheus?

Who are Lantheus' active insiders?

Are insiders buying or selling shares of Lantheus?